K Bartelheim

  • Citations Per Year
Learn More
3163 Background: MBT-0206 is a highly innovative anti-neovascular cytostatic compound designed to target and destroy newly formed tumor blood vessels. Its superior anti-tumor activity based on this new concept has been shown in several animal models. A phase I clinical study was conducted to determine dose-limiting toxicity (DLT), maximum-tolerated dose(More)
3079 Background: MBT-0206 is a highly innovative anti-neovascular cytostatic compound designed to target and destroy newly formed tumor blood vessels. Its superior anti-tumor activity based on this new concept has been shown in several animal models. In addition MBT-0206 (lipid-complexed paclitaxel) was shown to be effective in paclitaxel-resistant tumors.(More)
2544 Background: Peritoneal carcinomatosis (PC) due to GI-tract cancer is an advanced tumor stage with poor survival. At present, no standard therapy has been recommended, as chemotherapy and surgery showed only limited efficacy in affected patients. When applied intraperitoneally (i.p.), the trifunctional antibody catumaxomab could be shown to destroy(More)
  • 1